Advertisement

Michael R. Nazareth, MD, PhD, FAAD

Articles

Advertisement

Future Directions in the Management Atopic Dermatitis in Adult Patients

April 14, 2025

Panelists discuss how the future of atopic dermatitis treatments is evolving with novel biologics, Janus kinase inhibitors, and precision medicine targeting immune pathways. Advances in gene therapy, microbiome modulation, and personalized treatments offer promising long-term management options.

Multispecialty Perspectives on Shared Decision-Making in Atopic Dermatitis Care

April 07, 2025

Panelists discuss how shared decision-making in atopic dermatitis care involves collaboration between health care providers and patients, considering individual preferences, values, and treatment goals. This approach enhances treatment adherence and improves outcomes through personalized, informed choices.

Clinical Considerations for Choosing a Systemic Agent for Patients With Atopic Dermatitis

April 07, 2025

Panelists discuss how standard first-line treatments for nonresponsive patients often include systemic therapies like corticosteroids or immunomodulators. Second-line options may involve biologics or advanced systemic agents. Patient input is crucial in tailoring treatments to preferences, needs, and risks.

Evaluation of Long-Term Data With JAK Inhibitors

March 31, 2025

Panelists discuss how the JADE EXTEND study (Shi 2022) found that most patients who achieved EASI-75 with dupilumab also responded to abrocitinib. Even some dupilumab nonresponders achieved EASI-75. Adverse events (AEs) included nausea, acne, and headache.

Advertisement
Advertisement
Advertisement
x